摘要
目的探讨左乙拉西坦、丙戊酸钠治疗癫痫的临床效果及其对患儿骨代谢的影响。方法选择2015年1月至2018年5月洛阳新区人民医院收治的116例癫痫患儿为研究对象,根据治疗方法分为左乙拉西坦组(n=68)和丙戊酸钠组(n=48),另选择同期健康儿童34例作为健康对照组。分别于治疗前及治疗3、6个月时检测左乙拉西坦组和丙戊酸钠组患儿血清碱性磷酸酶(ALP)、钙(Ca^2+)、磷(P^3-)和25-羟基维生素D[25-(OH)D]水平,健康对照组儿童于体检时检测上述指标;治疗6个月后评估左乙拉西坦组和丙戊酸钠组患儿的临床疗效。结果治疗前3组儿童血清ALP、Ca ^2+、P ^3-、25-(OH)D水平比较差异无统计学意义(P>0.05)。左乙拉西坦组患儿治疗前、治疗3个月和治疗6个月血清ALP、Ca ^2+、P^3-、25-(OH)D水平比较差异无统计学意义(P>0.05);丙戊酸钠组患儿治疗前、治疗3个月和治疗6个月血清Ca^2+、P^3-、25-(OH)D水平比较差异无统计学意义(P>0.05),丙戊酸钠组患儿治疗6个月后血清ALP水平高于治疗前和治疗3个月(P<0.05)。治疗3个月后,左乙拉西坦组与丙戊酸钠组患儿血清ALP、Ca^2+、P^ 3-、25-(OH)D水平比较差异无统计学意义(P>0.05);治疗6个月后,左乙拉西坦组与丙戊酸钠组患儿血清Ca^2+、P^ 3-、25-(OH)D水平比较差异无统计学意义(P>0.05),丙戊酸钠组患儿血清ALP水平高于左乙拉西坦组(P<0.05)。治疗6个月后,左乙拉西坦组和丙戊酸钠组患儿总有效率分别为83.8%(57/68)、79.2%(38/48),2组患儿治疗总有效率比较差异无统计学意义(χ2=0.412,P>0.05)。结论左乙拉西坦和丙戊酸钠对癫痫患儿的疗效相当;左乙拉西坦对癫痫患儿骨代谢无显著影响;丙戊酸钠对癫痫患儿骨代谢有一定的影响,因此,应用丙戊酸钠治疗期间应注意监测血清ALP水平。
Objective To investigate the clinical effect of levetiracetam and sodium valproate in the treatment of epilepsy and its influence on bone metabolism in children.Methods A total of 116 children with epilepsy admitted to the People′s Hospital of Luoyang New District from January 2015 to May 2018 were selected as the subjects,and they were divided into levetiracetam group(n=68)and valproate group(n=48)according to the therapeutic method.Another 34 healthy children were selected as the healthy control group.The levels of serum alkaline phosphatase(ALP),calcium(Ca^2+),phosphorus(P^3-)and 25-hydroxyvitamin D[25-(OH)D]were detected before treatment and 3,6 months after treatment.The above indexes were detected in the healthy control group at the time of physical examination.The clinical effect of the children in the levetiracetam group and sodium valproate group was evaluated after 6 months of treatment.Results There was no significant difference in the levels of serum ALP,Ca^2+,P^3-and 25-(OH)D among the three groups before treatment(P>0.05).There was no significant difference in the levels of serum ALP,Ca^2+,P^ 3-and 25-(OH)D at the time points of before treatment,3 months and 6 months of treatment in the levetiracetam group(P>0.05).There was no significant difference in the levels of serum Ca^2+,P^ 3-and 25-(OH)D at the time points of before treatment,3 months and 6 months of treatment in the sodium valproate group(P>0.05).The serum ALP level after 6 months of treatment was higher than that before treatment and 3 months of treatment in the valproate group(P<0.05).There was no significant difference in the levels of serum ALP,Ca^2+,P^3-and 25-(OH)D between the levetiracetam group and the sodium valproate group after 3 months of treatment(P>0.05).After 6 months of treatment,there was no significant difference in the levels of serum Ca^2+,P^3-and 25-(OH)D between the levetiracetam group and the sodium valproate group(P>0.05),the serum ALP level in the valproate group was higher than that in the levetiracetam group(P<0
作者
乔喜娟
贺孝良
QIAO Xijuan;HE Xiaoliang(Department of Pediatrics,the People′s Hospital of Luoyang New District,Luoyang 471023,Henan Province,China;Department of Pediatrics,the First Affiliated Hospital of Henan University of Science and Technology,Luoyang 471000,Henan Province,China)
出处
《新乡医学院学报》
CAS
2020年第9期881-884,共4页
Journal of Xinxiang Medical University
关键词
癫痫
丙戊酸钠
左乙拉西坦
骨代谢
epilepsy
valproic acid
levetiracetam
bone metabolism
